GPR155

Summary

GPR155 (G protein-coupled receptor 155, HGNC:22951) is a protein-coding gene on chromosome 2q31.1, encoding Lysosomal cholesterol signaling protein (Q7Z3F1). Cholesterol-binding protein that acts as a regulator of mTORC1 signaling pathway.

Enables cholesterol binding activity. Involved in several processes, including cellular response to amino acid starvation; cellular response to cholesterol; and positive regulation of TORC1 signaling. Located in extracellular exosome. Is active in lysosomal membrane.

Source: NCBI Gene 151556 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 126 total
• MANE Select transcript: NM_152529

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:22951
Approved symbol	GPR155
Name	G protein-coupled receptor 155
Location	2q31.1
Locus type	gene with protein product
Status	Approved
Aliases	DEP.7, PGR22, DEPDC3, LYCHOS, FLJ31819
Ensembl gene	ENSG00000163328
Ensembl biotype	protein_coding
OMIM	620855
Entrez	151556

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 17 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000295500, ENST00000392551, ENST00000392552, ENST00000459996, ENST00000497620, ENST00000614352, ENST00000886491, ENST00000886492, ENST00000886493, ENST00000932232, ENST00000932233, ENST00000949639, ENST00000949640, ENST00000949641, ENST00000949642, ENST00000949643, ENST00000949644, ENST00000949645, ENST00000949646

RefSeq mRNA: 4 — MANE Select: NM_152529 NM_001033045, NM_001267050, NM_001267051, NM_152529

CCDS: CCDS2259, CCDS74605

Canonical transcript exons

ENST00000392552 — 16 exons

Exon	Start	End
ENSE00001073359	174459878	174460088
ENSE00001073362	174446611	174446747
ENSE00001073365	174466544	174466627
ENSE00001073368	174453737	174453841
ENSE00001274952	174486873	174487029
ENSE00002461373	174470390	174470555
ENSE00002463935	174461402	174461492
ENSE00002485287	174472965	174473364
ENSE00002498189	174465785	174465902
ENSE00002520336	174468912	174469067
ENSE00002528926	174461588	174461672
ENSE00002725526	174481497	174481987
ENSE00003533382	174439898	174440035
ENSE00003547554	174442119	174442183
ENSE00003614704	174445081	174445176
ENSE00003748476	174431571	174436416

Expression profiles

Bgee: expression breadth ubiquitous, 251 present calls, max score 97.73.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 10.5945 / max 833.6688, expressed in 1354 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
31865	10.0624	1344
31864	0.5321	239

Top tissues by expression

259 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
dorsal root ganglion	UBERON:0000044	97.73	gold quality
trigeminal ganglion	UBERON:0001675	97.62	gold quality
kidney epithelium	UBERON:0004819	94.69	gold quality
cardia of stomach	UBERON:0001162	94.31	gold quality
lateral globus pallidus	UBERON:0002476	93.82	gold quality
cerebellar vermis	UBERON:0004720	92.77	gold quality
middle temporal gyrus	UBERON:0002771	91.78	gold quality
Brodmann (1909) area 46	UBERON:0006483	91.67	gold quality
Brodmann (1909) area 23	UBERON:0013554	91.45	gold quality
lateral nuclear group of thalamus	UBERON:0002736	91.35	gold quality
parietal lobe	UBERON:0001872	90.86	gold quality
upper leg skin	UBERON:0004262	90.81	gold quality
endothelial cell	CL:0000115	90.64	gold quality
postcentral gyrus	UBERON:0002581	90.36	gold quality
superior vestibular nucleus	UBERON:0007227	90.06	gold quality
entorhinal cortex	UBERON:0002728	89.90	gold quality
medulla oblongata	UBERON:0001896	89.89	gold quality
upper arm skin	UBERON:0004263	89.88	gold quality
superior frontal gyrus	UBERON:0002661	89.73	gold quality
pons	UBERON:0000988	89.39	gold quality
nipple	UBERON:0002030	88.63	gold quality
dorsal plus ventral thalamus	UBERON:0001897	88.05	gold quality
occipital lobe	UBERON:0002021	87.95	gold quality
body of stomach	UBERON:0001161	87.89	gold quality
corpus epididymis	UBERON:0004359	87.83	gold quality
left ventricle myocardium	UBERON:0006566	87.71	gold quality
fundus of stomach	UBERON:0001160	87.56	gold quality
renal medulla	UBERON:0000362	87.36	gold quality
stomach	UBERON:0000945	87.14	gold quality
ventral tegmental area	UBERON:0002691	86.82	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-HCAD-11	yes	25.99
E-MTAB-8410	yes	22.18
E-CURD-46	yes	11.41
E-ANND-3	yes	5.56
E-MTAB-6386	no	134.52

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

192 targeting GPR155, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192

Literature-anchored findings (GeneRIF, showing 4)

• GPR155 may represent a biomarker for diagnosing and predicting hematogenous metastasis of gastric cancer. (PMID:28165032)
• Downregulation of GPR155 may serve as a prognosticator that also predicts initial recurrence sites independent of hepatitis virus infection. (PMID:28863781)
• Lysosomal GPCR-like protein LYCHOS signals cholesterol sufficiency to mTORC1. (PMID:36007018)
• Circular RNA hsa_circ_0094976 modulates GPR155 to inhibit gastric adenocarcinoma malignant characteristics by targeting miR-223-3p. (PMID:38678850)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	gpr155b	ENSDARG00000071086
danio_rerio	gpr155a	ENSDARG00000090804
mus_musculus	Gpr155	ENSMUSG00000041762
rattus_norvegicus	Gpr155	ENSRNOG00000018485
drosophila_melanogaster	anchor	FBGN0036741

Paralogs (3): PREX2 (ENSG00000046889), PREX1 (ENSG00000124126), DEPTOR (ENSG00000155792)

Protein

Protein identifiers

Lysosomal cholesterol signaling protein — Q7Z3F1 (reviewed: Q7Z3F1)

Alternative names: G-protein coupled receptor PGR22

All UniProt accessions (2): A0A087WXK4, Q7Z3F1

UniProt curated annotations — full annotation on UniProt →

Function. Cholesterol-binding protein that acts as a regulator of mTORC1 signaling pathway. Acts as a sensor of cholesterol to signal cholesterol sufficiency to mTORC1: in presence of cholesterol, binds cholesterol, leading to disruption of the interaction between the GATOR1 and KICSTOR complexes and promotion of mTORC1 signaling. Upon cholesterol starvation, GPR155/LYCHOS is unable to perturb the association between GATOR1 and KICSTOR, leading to mTORC1 signaling inhibition. Binds indole-3-acetic acid and may play a role in tryptophan metabolism.

Subunit / interactions. Homodimer; via the transporter region and DEP domain. Interacts with the GATOR1 complex and prevents interaction between GATOR1 and KICSTOR; this interaction is disrupted upon cholesterol starvation.

Subcellular location. Lysosome membrane.

Domain organisation. Cholesterol binds at the interface between the PIN-like transporter region and the GPCR domain; these two regions likely coordinate to sense cholesterol and regulate mTORC1 activation.

RefSeq proteins (4): NP_001028217, NP_001253979, NP_001253980, NP_689742* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000591	DEP_dom	Domain
IPR004776	Mem_transp_PIN-like	Family
IPR036388	WH-like_DNA-bd_sf	Homologous_superfamily
IPR036390	WH_DNA-bd_sf	Homologous_superfamily
IPR037368	GPR155_DEP	Domain
IPR051832	mTOR-Rac_regulators	Family

Pfam: PF00610, PF03547

UniProt features (120 total): helix 35, topological domain 18, transmembrane region 17, mutagenesis site 14, sequence conflict 9, strand 7, binding site 6, turn 5, glycosylation site 5, region of interest 2, chain 1, domain 1

Structure

Experimental structures (PDB)

23 structures.

PDB	Method	Resolution (Å)
8Z8Z	ELECTRON MICROSCOPY	2.11
8U5Q	ELECTRON MICROSCOPY	2.4
8U58	ELECTRON MICROSCOPY	2.45
8U54	ELECTRON MICROSCOPY	2.65
8U5C	ELECTRON MICROSCOPY	2.68
9JBH	ELECTRON MICROSCOPY	2.73
8U56	ELECTRON MICROSCOPY	2.75
8U5V	ELECTRON MICROSCOPY	2.77
8U5X	ELECTRON MICROSCOPY	2.79
9LHV	ELECTRON MICROSCOPY	2.79
8Y56	ELECTRON MICROSCOPY	2.83
8U5N	ELECTRON MICROSCOPY	3
8WR3	ELECTRON MICROSCOPY	3.1
9JBF	ELECTRON MICROSCOPY	3.21
9J3X	ELECTRON MICROSCOPY	3.3
9JBE	ELECTRON MICROSCOPY	3.31
9J40	ELECTRON MICROSCOPY	3.4
9LHQ	ELECTRON MICROSCOPY	3.46
9J3Z	ELECTRON MICROSCOPY	3.5
9JBJ	ELECTRON MICROSCOPY	3.73
9JBG	ELECTRON MICROSCOPY	3.76
9JBI	ELECTRON MICROSCOPY	4.49
9LHX	ELECTRON MICROSCOPY	5.62

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7Z3F1-F1	73.51	0.27

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (6): 43; 57; 266; 267; 268; 657

Glycosylation sites (5): 9, 15, 29, 309, 381

Mutagenesis-validated functional residues (14):

Position	Phenotype
43–44	nearly abolished cholesterol-binding.
43	strongly reduced cholesterol-binding.
48	does not affect cholesterol-binding.
57	strongly reduced cholesterol-binding. abolishes cholesterol-dependent mtorc1 activity.
145	reduces binding to indole-3-acetic acid.
148	reduces binding to indole-3-acetic acid.
177	reduces binding to indole-3-acetic acid.
352	abolishes the effect of cholesterol depletion in mtorc1 activity. abolishes the effect of cholesterol depletion in mtorc
551	abolished ability to regulate mtorc1.
595	in 4ca, abolished ability to regulate mtorc1; when associated with a-604, a-629 and a-638.
604	in 4ca, abolished ability to regulate mtorc1; when associated with a-595, a-629 and a-638.
629	in 4ca, abolished ability to regulate mtorc1; when associated with a-595, a-604 and a-638.
638	in 4ca, abolished ability to regulate mtorc1; when associated with a-595, a-604 and a-629.
678	abolishes the effect of cholestrol depletion in mtorc1 activity; when associated with a-352.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 261 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_DN, GSE45365_NK_CELL_VS_CD8_TCELL_UP, GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, GOBP_COGNITION, GOBP_CELLULAR_RESPONSE_TO_LIPID, GOCC_VACUOLAR_MEMBRANE, GOBP_POSITIVE_REGULATION_OF_TOR_SIGNALING, RACCACAR_AML_Q6, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, GOBP_REGULATION_OF_TRANSMEMBRANE_RECEPTOR_PROTEIN_SERINE_THREONINE_KINASE_SIGNALING_PATHWAY, GOBP_RESPONSE_TO_STEROL, GATA6_01, INGRAM_SHH_TARGETS_UP, GOBP_NEGATIVE_REGULATION_OF_BMP_SIGNALING_PATHWAY

GO Biological Process (15): negative regulation of BMP signaling pathway (GO:0030514), cellular response to amino acid starvation (GO:0034198), intracellular signal transduction (GO:0035556), cognition (GO:0050890), transmembrane transport (GO:0055085), cellular response to cholesterol (GO:0071397), positive regulation of TORC1 signaling (GO:1904263), cytoplasmic translation (GO:0002181), protein-containing complex localization (GO:0031503), cellular response to nutrient levels (GO:0031669), TORC1 signaling (GO:0038202), negative regulation of translational initiation (GO:0045947), positive regulation of translational initiation (GO:0045948), protein localization to lysosome (GO:0061462), negative regulation of TORC1 signaling (GO:1904262)

GO Molecular Function (2): cholesterol binding (GO:0015485), lipid binding (GO:0008289)

GO Cellular Component (4): lysosomal membrane (GO:0005765), extracellular exosome (GO:0070062), lysosome (GO:0005764), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
TORC1 signaling	2
regulation of TORC1 signaling	2
translational initiation	2
regulation of translational initiation	2
BMP signaling pathway	1
regulation of BMP signaling pathway	1
negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	1
negative regulation of cellular response to growth factor stimulus	1
cellular response to starvation	1
response to amino acid starvation	1
intracellular anatomical structure	1
signal transduction	1
nervous system process	1
transport	1
cellular process	1
cellular response to sterol	1
response to cholesterol	1
cellular response to alcohol	1
positive regulation of TOR signaling	1
translation	1
macromolecule localization	1
response to nutrient levels	1
cellular response to stimulus	1
TOR signaling	1
negative regulation of translation	1
positive regulation of translation	1
protein localization to vacuole	1
negative regulation of TOR signaling	1
sterol binding	1
alcohol binding	1
binding	1
lysosome	1
lytic vacuole membrane	1
extracellular vesicle	1
lytic vacuole	1
cellular anatomical structure	1

Protein interactions and networks

STRING

532 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GPR155	JAKMIP1	Q96N16	521
GPR155	MTCL2	O94964	519
GPR155	GPR137B	O60478	483
GPR155	TTC29	Q8NA56	453
GPR155	GPR137	Q96N19	450
GPR155	GPRC5C	Q9NQ84	444
GPR155	MORN5	Q5VZ52	412
GPR155	ZMYND15	Q9H091	399
GPR155	SCNM1	Q9BWG6	385
GPR155	RIBC1	Q8N443	384
GPR155	GPR152	Q8TDT2	382
GPR155	SLC60A1	Q8N468	377
GPR155	ZFYVE26	Q68DK2	375
GPR155	GPR82	Q96P67	366
GPR155	CYFIP1	Q7L576	365

IntAct

7 interactions, top by confidence:

A	B	Type	Score
FPR2	GPR89A	psi-mi:“MI:0914”(association)	0.350
FPR2	SCAMP3	psi-mi:“MI:0914”(association)	0.350
NIPAL3	ILVBL	psi-mi:“MI:0914”(association)	0.350
SLC16A8	C15orf61	psi-mi:“MI:0914”(association)	0.350
SLC35C2	PGRMC1	psi-mi:“MI:0914”(association)	0.350

BioGRID (7): GPR155 (Affinity Capture-MS), GPR155 (Proximity Label-MS), GPR155 (Proximity Label-MS), GPR155 (Affinity Capture-MS), GPR155 (Affinity Capture-MS), GPR155 (Affinity Capture-MS), GPR155 (Affinity Capture-MS)

ESM2 similar proteins: A0A452G813, A0A8V0ZB02, A1L3G9, A2AWR3, A9LIW2, B6HTR9, D3ZNF5, F4I248, F4JCY2, O35379, O57428, O94886, O94911, P08983, Q059Y8, Q06538, Q09427, Q09428, Q09429, Q17JQ7, Q3KTM2, Q3TWI9, Q4R7U0, Q4V8U5, Q5GH22, Q5GH60, Q5GH68, Q5R826, Q5R9A7, Q5T3F8, Q5YCC5, Q6NP91, Q6PP77, Q6UR05, Q7Q5R7, Q7Z3F1, Q7Z402, Q8C428, Q8CBX0, Q8CG09

Diamond homologs: A2AWR3, Q0CHV5, Q3LAC4, Q4PE51, Q570Y9, Q5R9A7, Q69ZK0, Q6CWI2, Q70Z35, Q7Z3F1, Q8TB45, Q8TCU6, Q8WZA2, Q9EQZ6, A1IGU3, A1IGU4, A3LRB2, E2RP94, E7F1U2, M0R4F8, O43307, P47170, P91620, P91621, Q1E9Q9, Q3UTH8, Q58DL7, Q5DU57, Q5RDK0, Q60992, Q6CAP3, Q6KAU7, Q6TXD4, Q6XZF7, Q75DV2, Q7TNR9, Q80VK6, Q96N96, Q9NR80, Q9NXL2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

126 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	103
Likely benign	5
Benign	4

Top pathogenic / likely-pathogenic (0)

SpliceAI

2937 predictions. Top by Δscore:

Variant	Effect	Δscore
2:174436171:T:A	donor_gain	1.0000
2:174436251:AT:A	donor_gain	1.0000
2:174436251:ATC:A	donor_gain	1.0000
2:174436252:T:C	donor_gain	1.0000
2:174439893:CTTA:C	donor_loss	1.0000
2:174439894:TTA:T	donor_loss	1.0000
2:174439895:TACC:T	donor_loss	1.0000
2:174439897:CCTT:C	donor_gain	1.0000
2:174440031:CAAGT:C	acceptor_gain	1.0000
2:174440032:AAGTC:A	acceptor_loss	1.0000
2:174440033:AGTC:A	acceptor_loss	1.0000
2:174440034:GT:G	acceptor_gain	1.0000
2:174440036:C:CC	acceptor_gain	1.0000
2:174440036:CT:C	acceptor_loss	1.0000
2:174440037:T:C	acceptor_loss	1.0000
2:174442114:TTTA:T	donor_loss	1.0000
2:174442115:TTACC:T	donor_loss	1.0000
2:174442116:TAC:T	donor_loss	1.0000
2:174442117:A:AG	donor_loss	1.0000
2:174442118:CCT:C	donor_loss	1.0000
2:174442118:CCTT:C	donor_gain	1.0000
2:174442184:CTAG:C	acceptor_loss	1.0000
2:174445116:A:C	donor_gain	1.0000
2:174445121:A:C	donor_gain	1.0000
2:174445132:T:TA	donor_gain	1.0000
2:174445175:TT:T	acceptor_gain	1.0000
2:174445177:C:CC	acceptor_gain	1.0000
2:174446609:A:AC	donor_gain	1.0000
2:174446610:C:CC	donor_gain	1.0000
2:174459876:A:AC	donor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000060635 (2:174477227 T>A), RS1000125780 (2:174479254 G>C), RS1000134341 (2:174449976 A>AAAAAC), RS1000205208 (2:174455476 C>A,G), RS1000207357 (2:174488521 A>G), RS1000273868 (2:174455843 T>G), RS1000367531 (2:174443313 A>G), RS1000396655 (2:174435498 G>T), RS1000410496 (2:174476927 T>G), RS1000460554 (2:174449529 T>C,G), RS1000611131 (2:174454383 C>T), RS1000695103 (2:174442917 C>T), RS1000723238 (2:174440745 T>C), RS1000723877 (2:174465572 G>T), RS1000768619 (2:174447495 G>A)

Disease associations

OMIM: gene MIM:620855 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST002827_3	Urate levels (BMI interaction)	1.000000e-07

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0004531	urate measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

44 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	8
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Smoke	increases expression, decreases expression	2
Tretinoin	increases expression, decreases expression	2
Cadmium Chloride	decreases expression, increases abundance, increases expression	2
Particulate Matter	decreases expression, increases abundance, increases expression	2
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
bisphenol A	affects cotreatment, increases expression	1
trichostatin A	affects expression	1
beta-lapachone	decreases expression	1
hydroquinone	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
di-n-butylphosphoric acid	affects expression	1
entinostat	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
beta-hydroxy simvastatin acid	increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Arbutin	decreases expression	1
Arsenic	affects methylation	1
Vehicle Emissions	increases abundance, increases expression	1
Benzo(a)pyrene	increases methylation	1
Cadmium	increases abundance, increases expression	1
Cisplatin	increases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Estradiol	affects cotreatment, decreases expression	1
Ethyl Methanesulfonate	increases expression	1
Indomethacin	affects cotreatment, increases expression	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D9FR	Ubigene HEK293 GPR155 KO	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.